The War on Drugs, Marijuana, Methadone & the Medications We Use for Sleep | Dr. Andrea Barthwell
What happens when addiction medicine, primary care, and national drug policy collide? On this episode of the Iron Direct Primary Care Podcast, Stefan Hartmann, PA-C sits down with Dr. Andrea Barthwell, one of the most experienced voices in American addiction medicine. Dr. Barthwell is a past president of the American Society of Addiction Medicine (ASAM) and served in the George W. Bush White House as Deputy Director for Demand Reduction at the Office of National Drug Control Policy (ONDCP). She is the founder of Encounter Medical Group and Two Dreams and was the founding chair of the $100 million Foundation for Opioid Response Efforts (FORE). This wasn't a conventional addiction-medicine interview. We discuss how American drug policy has changed—from the Bush-era War on Drugs and demand-reduction strategy to modern approaches emphasizing legalization, decriminalization, and harm reduction—and what decades of experience can teach us about the consequences of those choices. A major part of the conversation focuses on marijuana and the increasing tendency to treat cannabis as medicine or routine self-care. Dr. Barthwell explains her concerns about the medicalization of marijuana, particularly when patients assume that legalization or a medical-marijuana designation automatically means strong evidence of therapeutic benefit or long-term safety. We also go deep into something primary-care clinicians deal with every day: Sleep. Patients frequently arrive already using or requestingmedications such as: Eszopiclone (Lunesta) Trazodone Gabapentin Hydroxyzine Diphenhydramine (Benadryl) Atypical antipsychotics We discuss the tradeoffs of using psychoactive medications simply to make someone sleep, how dependence and substance-use history should change prescribing decisions, and why insomnia deserves more thoughtful evaluation than simply adding another sedating drug. We also discuss the role of primary care in identifying addiction early. Substance-use disorders do not always walk into the office announcing themselves. Alcohol, cannabis, prescription medications, stimulants, and opioids can become part of a patient's routine long before anyone formally identifies a disorder. Finally, Dr. Barthwell explains why she remains strongly supportive of evidence-based medications for opioid use disorder, including methadone and buprenorphine, and why these therapies should be viewed as medical treatment rather than simply substituting one drug for another. Topics include: • The War on Drugs and how American drug policy has evolved • Prevention, treatment, legalization, decriminalization, and harm reduction • The medicalization of marijuana • What the evidence actually supports for cannabis • Cannabis as a treatment for anxiety and insomnia • Primary-care screening for substance-use disorders • Alcohol and drug-use conversations in routine medicine • Insomnia and the medications commonly prescribed for sleep • Lunesta, trazodone, gabapentin, hydroxyzine and Benadryl • Atypical antipsychotics being used as sleep medications • Methadone for opioid-use disorder • Buprenorphine for opioid-use disorder • Why addiction treatment belongs in mainstream medicine • What primary-care clinicians can do differently This conversation is particularly relevant for primary-care clinicians because addiction isn't merely a specialty-care problem. It is a primary-care problem. The person struggling with alcohol, cannabis, opioids, sedatives, or stimulants may already be sitting in our exam room. The question is whether we recognize it. Iron Direct Primary Care Podcast Hosted by Stefan Hartmann, PA-C CEO, Iron Direct Primary Care If you would like to learn anti aging medicine for primary care check out HRTPCP.COM to take our HRT course Connect with Dr. Barthwell at https://www.linkedin.com/in/drandreabarthwell/ and twodreams.com
Comments